Pulmatrix Ownership
| PULM Stock | USD 8.39 0.07 0.83% |
Shares in Circulation | First Issued 2012-06-30 | Previous Quarter 3.7 M | Current Value 3.7 M | Avarage Shares Outstanding 1.2 M | Quarterly Volatility 1.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pulmatrix |
Pulmatrix Stock Ownership Analysis
The book value of the company was at this time reported as 2.99. The company recorded a loss per share of 2.64. Pulmatrix last dividend was issued on the 6th of February 2019. The entity had 1:20 split on the 1st of March 2022. Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. To find out more about Pulmatrix contact Teofilo MBA at 781 357 2333 or learn more at https://www.pulmatrix.com.Besides selling stocks to institutional investors, Pulmatrix also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pulmatrix's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pulmatrix's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pulmatrix Quarterly Liabilities And Stockholders Equity |
|
Pulmatrix Insider Trades History
Less than 1% of Pulmatrix are currently held by insiders. Unlike Pulmatrix's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pulmatrix's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pulmatrix's insider trades
Pulmatrix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulmatrix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulmatrix backward and forwards among themselves. Pulmatrix's institutional investor refers to the entity that pools money to purchase Pulmatrix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Investments N A | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-12-31 | 0.0 | Gradient Investments | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-12-31 | 0.0 | Northwestern Mutual Wealth Management Co | 2024-12-31 | 0.0 | Renaissance Technologies Corp | 2024-12-31 | 109.1 K | Sbi Securities Co Ltd | 2024-12-31 | 66.2 K | Blackrock Inc | 2024-12-31 | 54.9 K | Geode Capital Management, Llc | 2024-12-31 | 36.9 K | Vanguard Group Inc | 2024-12-31 | 35.1 K | State Street Corp | 2024-12-31 | 13.9 K |
Pulmatrix Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmatrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmatrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulmatrix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mcguire Terrance 2 days ago Acquisition by Mcguire Terrance of 124000 shares of Pulmatrix at 0.468 subject to Rule 16b-3 | ||
Bazemore Todd over a week ago Acquisition by Bazemore Todd of 30000 shares of Pulmatrix at 1.14 subject to Rule 16b-3 | ||
Sherman Matthew L over a week ago Acquisition by Sherman Matthew L of 124000 shares of Pulmatrix at 0.468 subject to Rule 16b-3 | ||
Siegert Michelle over three months ago Disposition of 25000 shares by Siegert Michelle of Pulmatrix at 1.06 subject to Rule 16b-3 | ||
Cabell Christopher over three months ago Acquisition by Cabell Christopher of 22100 shares of Pulmatrix at 0.3701 subject to Rule 16b-3 | ||
Gillis Steven over six months ago Acquisition by Gillis Steven of 111 shares of Pulmatrix at 110.0 subject to Rule 16b-3 | ||
Gillis Steven over six months ago Disposition of 880 shares by Gillis Steven of Pulmatrix at 28.0 subject to Rule 16b-3 | ||
Teofilo Raad over a year ago Acquisition by Teofilo Raad of 34900 shares of Pulmatrix subject to Rule 16b-3 |
Pulmatrix Outstanding Bonds
Pulmatrix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pulmatrix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pulmatrix bonds can be classified according to their maturity, which is the date when Pulmatrix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PulteGroup 6 percent Corp BondUS745867AT82 | View | |
| PulteGroup 55 percent Corp BondUS745867AW12 | View | |
| PulteGroup 5 percent Corp BondUS745867AX94 | View | |
| PulteGroup 7875 percent Corp BondUS745867AM30 | View | |
| PulteGroup 6375 percent Corp BondUS745867AP60 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Pulmatrix Corporate Filings
8K | 14th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 22nd of January 2025 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.